The Therapeutic Products Bill, promising to revolutionize the regulatory landscape for therapeutic goods in New Zealand, has stirred intense discussions among experts and industry insiders. A recent event that vividly encapsulated this discourse was the New Zealand HealthTech Week, where the director of the Johner Institute New Zealand, Anne Arndt, was invited to give her…

The difference between validation and verification, especially in the context of Software as a Medical Device (SaMD), can be quite nuanced and often confuses many. This is largely due to the fact that various regulatory bodies like the FDA, and international standards such as IEC 62304 and IEC 82304-1, may use these terms in slightly…

The FDA has recently released a new draft guidance on “Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions”. This draft guidance proposes a novel and flexible regulatory approach for AI/ML-based medical devices, inviting public comments until July 3, 2023. A significant tool that can help in…